Flamingo-01 Phase III GP2 Product Press Releases Email Alerts
Greenwich LifeSciences
  • ABOUT
    • MANAGEMENT TEAM
    • BOARD OF DIRECTORS
  • TECHNOLOGY
    • OUR GP2 CANCER IMMUNOTHERAPY PRODUCT
    • CANCER AND IMMUNOTHERAPY OVERVIEW
  • CLINICAL TRIALS
    • COMPLETED PHASE IIB CLINICAL TRIAL
    • FLAMINGO-01 PHASE III CLINICAL TRIAL
  • INVESTORS & MEDIA
    • OVERVIEW
    • NEWS & EVENTS
    • COMPANY INFO
    • STOCK INFO
    • SEC FILINGS
    • GOVERNANCE
  • CONTACT
  • ABOUT
    • MANAGEMENT TEAM
    • BOARD OF DIRECTORS
  • TECHNOLOGY
    • OUR GP2 CANCER IMMUNOTHERAPY PRODUCT
    • CANCER AND IMMUNOTHERAPY OVERVIEW
  • CLINICAL TRIALS
    • COMPLETED PHASE IIB CLINICAL TRIAL
    • FLAMINGO-01 PHASE III CLINICAL TRIAL
  • INVESTORS & MEDIA
    • OVERVIEW
    • NEWS & EVENTS
    • COMPANY INFO
    • STOCK INFO
    • SEC FILINGS
    • GOVERNANCE
  • CONTACT

Press Releases

Nasdaq: GLSI

Investors

  • Overview
  • News & Events
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Presentations
    • FAQ
  • Stock Info
  • SEC Filings
  • Governance
  • News & Events

  • Press Releases
  • IR Calendar
  • Email Alerts
Dec 22, 2020 10:12am EST

Greenwich LifeSciences, Inc. Announces Closing of Public Offering of Common Stock

Dec 18, 2020 6:00am EST

Greenwich LifeSciences, Inc. Prices $26.4 Million Upsized Public Offering of Common Stock

Dec 15, 2020 6:00am EST

Greenwich LifeSciences Announces Option Agreement for Pre-clinical Coronavirus Vaccine Candidates

Dec 11, 2020 6:00am EST

Greenwich LifeSciences Announces Poster Presentation on Its GP2 Phase III Clinical Trial Design for Recurring Breast Cancer

Dec 09, 2020 9:05am EST

Greenwich LifeSciences Announces Poster Presentation of Five Year Data for GP2 Phase IIb Clinical Trial, Showing 0% Recurrence of Breast Cancer

Dec 03, 2020 7:00am EST

Greenwich LifeSciences Announces New Manufacturing Agreement for its Planned Phase III Clinical Trial and Enters into Lease for Office and Lab Space

Dec 02, 2020 7:00am EST

Greenwich LifeSciences to Present at the Annual LD Micro Main Event

Nov 23, 2020 7:00am EST

Greenwich LifeSciences Announces Second Publication and Second Poster Presentation of Phase III Clinical Trial of Potential Breakthrough Technology for Recurring Breast Cancer

Nov 18, 2020 7:00am EST

Greenwich LifeSciences Announces Publication of Positive Phase IIb Clinical Trial Data for GP2, Its Lead Drug Candidate for the Prevention of Recurring Breast Cancer

Nov 12, 2020 9:00am EST

Greenwich LifeSciences, Inc. Announces Partnership with Baylor College of Medicine for its Planned Phase III Clinical Trial

  • Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • Next
RSS

By proceeding to use this website, you consent to our use of cookies as described in our Privacy Policy.

Email Alerts

Sign up Now

Sign me up for:

  • Tear Sheet
  • RSS Feed
Logo of Greenwich LifeSciences.

Copyright © 2023

Greenwich LifeSciences, Inc.

ABOUT
TECHNOLOGY
CLINICAL TRIALS
INVESTORS & MEDIA
CONTACT
Privacy Policy
Disclaimer
Sitemap
Logo of Greenwich LifeSciences.

Copyright © 2023

Greenwich LifeSciences, Inc.

ABOUT
TECHNOLOGY
CLINICAL TRIALS
INVESTORS & MEDIA
CONTACT
Disclaimer
Privacy Policy
Sitemap